DarioHealth's Upcoming Earnings: What to Anticipate Now
Understanding DarioHealth's Earnings Report
DarioHealth DRIO is set to release its latest quarterly earnings report on an upcoming Tuesday. Investors should be adequately prepared as this announcement approaches and consider the vital information shared here.
Analyst Projections
Analysts anticipate that DarioHealth will report an earnings per share (EPS) of approximately $-0.14. This figure will be crucial in shaping investor sentiment as the earnings report date approaches.
Anticipation Among Investors
The environment surrounding DarioHealth's upcoming announcement is filled with excitement. Investors are eager to see if the company can meet or exceed expectations and what guidance will be provided for the next quarter. This guidance often proves more impactful than the earnings numbers themselves in swaying market sentiment.
Past Performance Insights
It’s important for potential investors to examine past earnings reports. In the last quarter, DarioHealth fell short of EPS estimates by $0.07, resulting in a share price decrease of 0.76% the following day. Such performance metrics can help investors understand potential future swings in stock price.
Historical Earnings Data
Here's a brief overview of DarioHealth's recent earnings performance:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.05 | -0.14 | -0.27 | -0.55 |
| EPS Actual | -0.12 | -0.04 | -0.18 | -0.20 |
| Price Change % | -1.0% | -7.0% | -5.0% | -5.0% |
Current Market Performance
As of recent trading data, shares of DarioHealth are valued at $0.5398. Over the past year, the stock has experienced a decline of 44.09%. Long-term investors are likely feeling disheartened about the negative return on their investments heading into this earnings release.
Current Analyst Sentiments
Gaining insights into market expectations is key for investors. Presently, DarioHealth holds a consensus rating of Buy based on 1 analyst rating. The average price target over the next year is set at $3.00, indicating a promising upside potential of approximately 455.76%. This anticipated growth may shift investor perceptions.
Comparative Analysis with Peers
In examining the broader healthcare industry, it’s essential to note how DarioHealth stands against its peers, including American Well and Health Catalyst.
- American Well is currently rated Neutral with a one-year price target of $10, forecasting a potential upside of 1752.54%.
- Health Catalyst has a Neutral rating, with a one-year price target of $4.4, which suggests a potential increase of 715.12%.
- Simulations Plus is rated Buy, with its target price set at $26.5, suggesting an impressive upside of 4809.23%.
Key Metrics Overview
During this comparative analysis, important metrics for these companies were highlighted:
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| DarioHealth | Buy | 17.26% | $3.88M | -19.31% |
| American Well | Neutral | 12.91% | $39.76M | -6.83% |
| Health Catalyst | Neutral | 1.65% | $36.23M | -11.31% |
| Simulations Plus | Buy | 9.81% | $13.03M | -42.97% |
About DarioHealth
DarioHealth Corp specializes in digital therapeutics (DTx), providing personalized, data-driven interventions utilizing advanced software and analytics. The company's multidisciplinary team integrates life sciences and behavioral science to deliver effective therapeutic solutions across various health conditions.
A Glimpse into DarioHealth's Financials
Market Capitalization: DarioHealth's market cap is notably lower than its industry peers, indicating its relatively small size.
Recent Revenue Growth: Recently reported revenue growth stands at a significant 17.26%, demonstrating the potential increase in earnings compared to competitors.
Profitability: DarioHealth's net margin of -208.32% suggests challenges in profitability, reinforcing the need for strategic financial management.
Debt Management: A notable point is the company's debt-to-equity ratio of 0.41, indicating less reliance on debt financing, showcasing prudent financial practices.
Frequently Asked Questions
When is DarioHealth's next earnings report?
DarioHealth is expected to announce its quarterly earnings on an upcoming Tuesday.
What are the expected earnings for DarioHealth?
Analysts estimate that DarioHealth will have an EPS of approximately $-0.14.
What is DarioHealth's stock performance over the last year?
Over the past year, shares of DarioHealth have decreased by 44.09%.
What is today's stock price for DarioHealth?
As of August 08, shares are trading at approximately $0.5398.
What do analysts say about DarioHealth?
The consensus rating among analysts is Buy, with an average price target of $3.0.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.